Abbott and Stereotaxis, have joined forces to improve the treatment of abnormal heart rhythms. By integrating their respective technologies, the two companies have created a powerful combination that provides highly detailed real-time diagnostic information along with the precision and stability of robotics during therapy delivery. This integration not only enhances the physician experience but also streamlines procedural workflow, ultimately improving patient outcomes.
Following successful integration and testing, Abbott and Stereotaxis have obtained regulatory clearance for the use of their integrated technologies in Europe, with additional clearances anticipated in the near future. This collaboration marks a significant milestone for the field of electrophysiology and has garnered positive feedback from experts in the medical community.
Dr. J. Peter Weiss, an electrophysiologist and clinical professor of medicine at Banner University of Arizona Medical Center, commended the joint use of Abbott’s EnSite X System with Stereotaxis’ Robotic Magnetic Navigation. He emphasized that this combination greatly benefits a wide range of cardiac ablation procedures and has a particularly powerful impact on treating complex and challenging cardiac arrhythmias.
Abnormal heart rhythms, known as arrhythmias, affect millions of individuals worldwide and can have severe consequences if left untreated, including an increased risk of stroke, heart failure, and sudden cardiac arrest. Abbott’s EnSite X System, a cardiac mapping innovation, received clearance from the US FDA in 2021. Stereotaxis’ Robotic Magnetic Navigation introduces the advantages of robotic precision, stability, and safety to cardiac ablation procedures by utilizing advanced computer-controlled magnetic fields to control the catheter tip directly.
David Fischel, Chairman and CEO of Stereotaxis, highlighted the company’s commitment to advancing medical progress through meaningful innovations. He emphasized that this partnership offers additional choices for the community of robotic users, ensuring that patients, physicians, and providers can benefit from the combination of the finest diagnostic and therapeutic technologies.